Zoetis Inc Stock Price, News & Analysis

Zoetis (NYSE: ZTS) has announced the election of Dr. Mark Stetter to its Board of Directors, effective May 21, 2025. Dr. Stetter, currently serving as Dean of the University of California, Davis School of Veterinary Medicine, brings extensive experience in veterinary medicine and animal health to the company. He will serve on the Board's Quality and Innovation Committee.

Dr. Stetter's diverse career spans roles at UC Davis, Colorado State University, The Walt Disney Company, The Bronx Zoo/Wildlife Conservation Society, and the Audubon Nature Institute. He holds a Doctor of Veterinary Medicine and a Bachelor of Science in biochemistry and chemistry from the University of Illinois at Champaign-Urbana.

Zoetis (NYSE: ZTS) has announced its third quarter 2025 dividend payment. The company's Board of Directors has declared a dividend of $0.50 per share, which will be distributed to shareholders on September 3, 2025. To be eligible for this dividend payment, investors must be holders of record of Zoetis common stock by the close of business on July 18, 2025.

Zoetis (NYSE: ZTS) has announced its participation in three upcoming investor conferences in May and June 2025:

• BNP Paribas Animal Health Day on May 22, 2025 at 1:00 p.m. ET
• Stifel 2025 Jaws and Paws Conference on May 29, 2025 at 9:10 a.m. ET
• William Blair 45th Annual Growth Stock Conference on June 3, 2025 at 10:40 a.m. CT

Live audio webcasts of the presentations will be accessible through Zoetis's investor relations website, with replays available after each event.

Zoetis (ZTS) reported strong Q1 2025 financial results with revenue of $2.2 billion, up 1% year-over-year and 9% on an organic operational basis. Net income reached $631 million ($1.41 per diluted share), increasing 5% and 8% respectively. The U.S. segment generated $1.2 billion in revenue (+2%), while International revenue remained flat at $1.0 billion but grew 11% organically.

The company's growth was primarily driven by companion animal products, particularly Simparica Trio, Apoquel, Cytopoint, and monoclonal antibodies Librela and Solensia. Zoetis updated its 2025 guidance, projecting revenue between $9.425-$9.575 billion and adjusted EPS of $6.20-$6.30, maintaining organic operational revenue growth of 6-8% but revising organic operational adjusted net income growth to 5-7% due to enacted tariffs.

Zoetis (NYSE:ZTS) has announced it will host a webcast and conference call on Tuesday, May 6, 2025, at 8:30 a.m. (ET) to discuss its first quarter 2025 financial results. CEO Kristin Peck and CFO Wetteny Joseph will lead the presentation and answer questions from financial analysts. The event will be accessible to investors and the public through the company's investor relations website, with pre-registration currently available.

Zoetis Inc. (NYSE:ZTS) has announced its participation in two upcoming investor conferences in early 2025. The company will be present at the Bank of America Securities 2025 Animal Health Summit on Thursday, February 27, 2025, at 1:20 p.m. ET, and the Barclays Global Healthcare Conference on Tuesday, March 11, 2025, at 10:30 a.m. ET.

Investors and interested parties can access live audio webcasts of both presentations through the company's investor relations website at http://investor.zoetis.com/events-presentations. Replay options will be available on the website after the conclusion of each event.

Zoetis (ZTS) has received a conditional license from the USDA's Center for Veterinary Biologics for its Avian Influenza Vaccine, H5N2 Subtype, Killed Virus for use in chickens. The license was granted based on safety, purity, and reasonable efficacy expectations from serology data.

The vaccine addresses the Highly Pathogenic Avian Influenza (HPAI) crisis, which has affected over 150 million birds in the U.S. since February 2022. The conditional license is issued for a time to meet emergency conditions and can be renewed at the CVB's discretion.

This development builds on Zoetis's extensive experience in avian influenza vaccines, including their 2016 H5N1 vaccine for the USDA's National Veterinary Stockpile and their POULVAC® FLUFEND™ i AI H5N3 RG vaccine used internationally.

Zoetis (NYSE: ZTS) reported strong financial results for Q4 and full year 2024. In Q4, revenue reached $2.3 billion, up 5% year-over-year, with net income of $581 million ($1.29 per diluted share), increasing 11% and 13% respectively. The company achieved 9% organic operational growth in Q4 after accounting for recent divestitures.

For full year 2024, Zoetis posted revenue of $9.3 billion, growing 8%, with net income of $2.5 billion ($5.47 per diluted share), up 6% and 8% respectively. The company delivered 11% operational growth in revenue and 15% operational growth in adjusted net income.

Looking ahead to 2025, Zoetis projects revenue between $9.225-$9.375 billion, with expected organic operational growth of 6-8%. The company forecasts diluted EPS of $5.70-$5.80 on a reported basis, or $6.00-$6.10 on an adjusted basis.

The Zoetis (NYSE:ZTS) Board of Directors has announced a quarterly dividend of $0.50 per share for the second quarter of 2025. The dividend will be distributed on June 3, 2025, to shareholders of record as of the close of business on April 21, 2025.